Your browser doesn't support javascript.
loading
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.
Carbonell, Caterina; Frigola, Joan; Pardo, Nuria; Callejo, Ana; Iranzo, Patricia; Valdivia, Augusto; Priano, Ilaria; Cedrés, Susana; Martinez-Marti, Alex; Navarro, Alejandro; Lenza, Laura; Soleda, Mireia; Gonzalo-Ruiz, Javier; Vivancos, Ana; Sansó, Miriam; Carcereny, Enric; Morán, Teresa; Amat, Ramon; Felip, Enriqueta.
Afiliação
  • Carbonell C; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Frigola J; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Pardo N; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Callejo A; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Iranzo P; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Valdivia A; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
  • Priano I; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Cedrés S; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
  • Martinez-Marti A; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Navarro A; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
  • Lenza L; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Soleda M; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
  • Gonzalo-Ruiz J; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
  • Vivancos A; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Sansó M; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
  • Carcereny E; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Morán T; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
  • Amat R; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.
  • Felip E; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
Mol Oncol ; 17(5): 779-791, 2023 05.
Article em En | MEDLINE | ID: mdl-36852704
ABSTRACT
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients benefit from this type of treatment. Here, we assessed the value of shallow whole-genome sequencing (sWGS) on plasma samples to monitor ICI benefit. We applied sWGS on cell-free DNA (cfDNA) extracted from plasma samples of 45 patients with metastatic NSCLC treated with ICIs. Over 150 samples were obtained before ICI treatment initiation and at several time points throughout treatment. From sWGS data, we computed the tumor fraction (TFx) and somatic copy number alteration (SCNA) burden and associated them with ICI benefit and clinical features. TFx at baseline correlated with metastatic lesions at the bone and the liver, and high TFx (≥ 10%) associated with ICI benefit. Moreover, its assessment in on-treatment samples was able to better predict clinical efficacy, regardless of the TFx levels at baseline. Finally, for a subset of patients for whom SCNA burden could be computed, increased burden correlated with diminished benefit following ICI treatment. Thus, our data indicate that the analysis of cfDNA by sWGS enables the monitoring of two potential biomarkers-TFx and SCNA burden-of ICI benefit in a cost-effective manner, facilitating multiple serial-sample analyses. Larger cohorts will be needed to establish its clinical potential.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Ácidos Nucleicos Livres / DNA Tumoral Circulante / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Ácidos Nucleicos Livres / DNA Tumoral Circulante / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article